

ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Either Same Or Both If Only One Number)	Maximum Number Of Patients Agreed (Either Same Or Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments	Errors
2700	15/WM/0128	195518	A Multicenter Double-Blind, Randomized Controlled Study of Etenacip and M...	Number Agreed	5	5	Date Agreed	29/04/2017	4	07/06/2017	4	Recruitment Finished		
2701	16/LO/1381	211114	A110E A mc, randomized, double-blind, placebo-controlled, 52 weeks study to	Number Agreed	2	2	Date Agreed	20/04/2017	2	11/04/2017	2	Recruitment Finished		
2702	15/WS/0065	178522	COMMANDERHF: Rivaroxaban in patients with decompensated HF	Number Agreed	5	5	Date Agreed	15/10/2017	4	27/07/2017	4	Recruitment Finished	target number of patients recruited earlier than planned date	
2703	16/LO/1386	199366	IDEA-HF A Phase 2 Randomised, Double-Blinded, Placebo-Controlled Study to	Number Agreed	4	4	Date Agreed	01/08/2017	0	15/08/2017	0	Recruitment Finished	difficult to recruit to	
2704	17/HEA/1441	20644	SMART: Effectiveness of Topoglif in treating Type 2 diabetes	Number Agreed	40	40	Date Agreed	05/12/2017	40	05/12/2017	40	Recruitment Finished		
2705	17/WW/0019	212375	SMARTS WITHDRAWAL STUDY	Number Agreed	4	4	Date Agreed	20/03/2018	2	17/10/2017	2	Recruitment Finished	Recruitment closed early, due to recruitment targets being met	
2706	16/WW/0586	209788	ASAP 4754: Non-interventional study on Edoxaban treatment in routine clinical	Number Agreed	30	30	Date Agreed	12/11/2016	37	21/01/2018	37	Recruitment Finished		
2707	16/LO/1830	209789	UTX TOR 304: A Phase 3, Randomized Study to Assess the Efficacy and Safety of	Number Agreed	3	3	Date Agreed	19/10/2016	0	13/07/2018	0	Recruitment Finished	Ethical concerns regarding radiation dose used by radiology professionals, followed by contracting delays with sponsors (at least 1/3). Recruitment then closed early.	
2708	05/LO/2067/08	33077	Prostate Adenocarcinoma: TransCutaneous Hormones: A randomised controlled	Number Agreed	10	10	Date Agreed	03/10/2011	9	31/03/2018	9	Recruitment Finished	Closed according to schedule	